Kymera Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Current Ratio Growth & History (KYMR)
Kymera Therapeutics's current ratio was 10.47 for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 10.47 | 2.94 | +39.05% |
| 2024 | 2024-12-31 | 7.53 | 2.80 | +59.19% |
| 2023 | 2023-12-31 | 4.73 | −1.15 | −19.54% |
| 2022 | 2022-12-31 | 5.88 | 1.00 | +20.56% |
| 2021 | 2021-12-31 | 4.88 | 2.14 | +78.41% |
| 2020 | 2020-12-31 | 2.73 | 0.05 | +1.77% |
| 2019 | 2019-12-31 | 2.69 | — | — |
Kymera Therapeutics quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 10.34 | 2.02 | +24.24% |
| Q1 2026 | 2026-03-31 | 10.81 | 2.32 | +27.34% |
| Q4 2025 | 2025-12-31 | 10.47 | 2.94 | +39.05% |
| Q3 2025 | 2025-09-30 | 7.38 | −1.17 | −13.65% |
| Q2 2025 | 2025-06-30 | 8.32 | −0.13 | −1.60% |
| Q1 2025 | 2025-03-31 | 8.49 | −1.08 | −11.27% |
| Q4 2024 | 2024-12-31 | 7.53 | 2.80 | +59.19% |
| Q3 2024 | 2024-09-30 | 8.55 | 2.60 | +43.72% |
| Q2 2024 | 2024-06-30 | 8.45 | 1.40 | +19.78% |
| Q1 2024 | 2024-03-31 | 9.57 | 2.93 | +44.02% |
| Q4 2023 | 2023-12-31 | 4.73 | −1.15 | −19.54% |
| Q3 2023 | 2023-09-30 | 5.95 | 0.53 | +9.71% |
| Q2 2023 | 2023-06-30 | 7.06 | 2.46 | +53.34% |
| Q1 2023 | 2023-03-31 | 6.65 | 1.76 | +36.08% |
| Q4 2022 | 2022-12-31 | 5.88 | 1.00 | +20.56% |
| Q3 2022 | 2022-09-30 | 5.42 | −0.33 | −5.78% |
| Q2 2022 | 2022-06-30 | 4.60 | 1.25 | +37.14% |
| Q1 2022 | 2022-03-31 | 4.88 | 1.79 | +57.82% |
| Q4 2021 | 2021-12-31 | 4.88 | 2.14 | +78.41% |
| Q3 2021 | 2021-09-30 | 5.75 | 2.98 | +107.61% |
| Q2 2021 | 2021-06-30 | 3.36 | — | — |
| Q1 2021 | 2021-03-31 | 3.09 | — | — |
| Q4 2020 | 2020-12-31 | 2.73 | 0.05 | +1.77% |
| Q3 2020 | 2020-09-30 | 2.77 | — | — |
| Q4 2019 | 2019-12-31 | 2.69 | — | — |
Kymera Therapeutics current ratio trends
Over the last five fiscal years, Kymera Therapeutics's current ratio increased from 2.73 to 10.47, a change of 7.74. The latest reported quarter, Q2 2026, shows 10.34.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗